Global Health Ventures Inc.
OTC Bulletin Board : GHLV

Global Health Ventures Inc.

October 12, 2010 09:25 ET

Global Health Ventures Reports Highly Positive Data on X-Excite

VANCOUVER, BRITISH COLUMBIA--(Marketwire - Oct. 12, 2010) - Global Health Ventures Inc. (OTCBB:GHLV) (the "Company") is a specialty pharmaceutical company focused on sublingual (under the tongue) drug delivery. The Company is pleased to announce the latest report on the development of its lead therapeutics drug, X-Excite. X-Excite is the Company's most advanced drug for male sexual enhancement and erectile dysfunction market. The Company had engaged a third party company to conduct a side by side study of X-Excite with Viagra® to compare dissolution and bioavailability. The fact that the new formulation is able to deliver the drug faster is highly dependent on the drug's dissolution profile and subsequently its bioavailability. The study was conducted under USP protocol and is now completed. The study showed that X-Excite is 6 times (600%) faster/quicker in dissolution and bioavailability than the commonly prescribed Viagra®. This means X-Excite is absorbed faster and it produces results in far less time than Viagra®. With this report, X-Excite has achieved remarkably positive results.

The Company's sublingual formulation is designed to enhance drugs to be delivered to the body without the need for injection. This design enables the vast majority of pharmaceutical drugs to be rapidly absorbed through the mucosal membrane (tissues of the mouth) quickly and efficiently. This technology works well for drugs that need faster results and have major side effects associated with gastrointestinal and/or liver break down. It is scientifically accepted that sublingual drug delivery route is the fastest and most efficient way of drug delivery after direct injection.

"We are very pleased with the results of this third party study. We are now awaiting the completion of our stability study which will be completed by the third week of October. We will then submit the data and the entire medical dossier to the European regulatory bodies for approval to initiate a quick human biocompatibility trial. We are now highly optimistic that the drug shall continue to perform well in the various processes of testing and approval," said Dr. Hassan Salari, Global Health President & CEO.

About Global Health Ventures

Global Health Ventures is a specialty pharmaceutical company with expertise in drug delivery and formulation. The Company has a proprietary platform technology for drug delivery via the sublingual (under the tongue) route. This unique method delivers drugs to the bloodstream quickly with minimal drug breakdown in the liver or gastrointestinal system, a process that can greatly reduce side effects associated with the drugs. The Company's lead therapeutic product is a male sexual enhancement drug that is delivered via sublingual route and is called X-Excite. In experimental studies, X-Excite has been shown to reach the blood stream rapidly, producing maximal effect and having less of the unwanted side effects associated with oral delivery route. X-Excite is presently in clinical development in Europe. The Company's second drug "Relax-B" is also under development in Canada for anxiety. And, the third drug will be an anti-migraine drug. The Company plans to use the same technology to deliver a vast number of other FDA approved and non-approved drugs that require faster delivery, or reduced hepatic and gastrointestinal side effects. These include stress relief, sleeping disorders, pain killers, anti-allergy medications, energy boosters and addiction replacement therapies.

Notice Regarding Forward Looking Statements - This press release includes forward-looking statements that involve a number of risks and uncertainties, including the success of the products in commercializing and developing. Further, the risks involve the ability of the Company to raise capital to fund its operations and the capital requirements for the development and marketing of its products. Investors are encouraged to review the risk factors listed or described from time to time in the Company's filings (10K) with the Securities and Exchange Commission.

Contact Information